Skip to main content
Clinical Trials/NCT04679324
NCT04679324
Withdrawn
Not Applicable

The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridiodes Difficile Infection

Mayo Clinic0 sitesSeptember 23, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Clostridioides Difficile Infection
Sponsor
Mayo Clinic
Primary Endpoint
Disease recurrence
Status
Withdrawn
Last Updated
3 years ago

Overview

Brief Summary

The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been diagnosed with C. difficile infection to determine if there are features associated with development, clearance, and recurrence of disease.

Detailed Description

Patients who were recently diagnosed with C. difficile infection will undergo assessment of both before treatment and after completing treatment to study the presence of C. difficile in the colonic mucosa pre as well as assessment for microbiome and patient/clinical factors that may contribute to disease recurrence. Assessment will include sigmoid colon biopsies, blood draw, stool samples and surveys.

Registry
clinicaltrials.gov
Start Date
September 23, 2019
End Date
August 10, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Purna C. Kashyap, MBBS

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Adults aged 18 and over
  • Confirmed C. difficile infection based on positive C. difficile toxin PCR testing and clinical evidence of diarrhea

Exclusion Criteria

  • Known active pregnancy
  • Prior diagnosis of C. difficile infection within 2 months of this diagnosis
  • Other known active gastrointestinal infectious process
  • Vulnerable adults
  • Any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes

Outcomes

Primary Outcomes

Disease recurrence

Time Frame: 8 weeks post treatment of C.difficile infection

Based on clinical stool testing and symptoms

Secondary Outcomes

  • Change in mucosal presence of C. difficile(Baseline, approximately 1-14 days post treatment of C. difficile infection)

Similar Trials